Hypothesis-Generating Brief: Pcsk9 Inhibitors Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename the 'Longevity' outcome class to reflect the actual endpoint (e.g. 'Lipoprotein(a) / MACE in CHD') so the map labels are not misleading.
2. Surface every admitted bundle source in the Findings Map (or explicitly list the unmapped sources in Limitations) so the auditable claim of source attribution holds for all 36 admitted sources.
3. Integrate the positive/null MACE and mortality signals from Karatasakis 2017, Imran 2023, Du 2019, Khan 2018, Wang 2022a, Wang 2022b, and Raone 2025 into a coherent cardiometabolic sub-narrative rather than leaving direction coded 'unclear' without explanation.
4. Expand the Tensions and Gaps section into a substantive paragraph or bulleted list that names the specific cross-source disagreements (e.g. mortality effect, SCD/arrhythmia, bone/skeletal signal, cognitive safety) rather than gesturing at 106 disagreements as a single number.
5. Reduce the per-source template repetition in the Findings Map; consolidate source-level entries into outcome-class summaries with citation lists, while preserving the per-source attribution audit trail.

Major issues

• The Findings Map presents source-level findings as a repetitive sequence of near-identical template blocks (one per outcome class) with mechanical restatement of the same boilerplate disclaimers, which undermines read-through synthesis and makes the landscape harder to audit than a tighter tabular map would be.
• Direction reconciliation is inconsistently applied: several cited sources in the bundle (e.g. Karatasakis 2017, Imran 2023, Du 2019, Khan 2018, Wang 2022a) report positive or null effects on MACE/mortality, but the map codes many as 'unclear' and never integrates these signals into a coherent cardiometabolic summary, leaving 106 load-bearing cross-source disagreements under-resolved rather than mapped.

Minor issues

• Several bundle sources (Hosseini 2024, Schmidt 2017, Wang 2022a, Du 2019, Khan 2018, Turgeon 2018) are referenced in the source bundle but not surfaced in the Findings Map tables, which weakens the auditable claim that the map covers the admitted corpus.
• The 'Longevity' outcome class is mislabeled for a PCSK9 inhibitors map: Hu 2025 is about MACE and Lp(a) in coronary heart disease, not longevity; the class label should be renamed to reflect actual content.
• Masson 2026 and Ariyanti 2026 (and possibly other bundle entries) do not appear in the narrative findings map despite being in the source bundle, creating an incomplete landscape.
• The Tensions and Gaps section is one short paragraph and does not name the specific cross-source disagreements it claims to surface.
• Several in-text source-citation names (e.g. Karatasakis 2017, Schmidt 2017) are present in the bundle but missing from the Findings Map's surfaced sources, which breaks the 'every mapped finding is attributed to specific cited sources' check.

Reviewer note

Evidence-map review of 'Pcsk9 Inhibitors Effects.' The scope is explicitly bounded (36 admitted sources across 8 outcome classes, 3 direct), the search summary is detailed and auditable, and the manuscript correctly avoids collapsing into a single causal, clinical, or policy conclusion. The honesty note that 33/36 sources are indirect/review-level is appropriate and the abstract and scope correctly bound interpretation. Source grounding is strong: cited_as entries in the prose trace to specific bundle records, and DOIs/titles match. Weaknesses: (1) The Findings Map is largely mechanical repetition of the same boilerplate per outcome class, which is faithful to the data but makes the synthesis hard to read and obscures the actual cross-source heterogeneity. (2) Several bundle sources (Hosseini 2024, Schmidt 2017, Wang 2022a, Du 2019, Khan 2018, Turgeon 2018, Masson 2026, Ariyanti 2026) are not surfaced in the Findings Map, which violates the 'every mapped finding is attributed' check for the full corpus. (3) The 'Longevity' class label is misleading for Hu 2025, which is a MACE/Lp(a) CHD meta-analysis. (4) The Tensions and Gaps section is too thin to function as an explicit disagreement-mapping section. (5) Direction coding is conservative but inconsistent: well-known MACE-positive meta-analyses (Karatasakis 2017, Du 2019, Khan 2018) are coded 'unclear' or 'null' without explanation, leaving the 106 cross-source disagreements under-resolved rather than mapped. No major overclaim: the conclusion is appropriately bounded. No reviewer-directed instructions were detected in the manuscript. Calibration: the manuscript is credible and explicitly incomplete (sparse direct evidence, mixed findings, heterogeneous outcomes), so revise is the correct call. Required revisions are bounded and feasible.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis